Most Active Stocks in Pre-Market Trading on November 10, 2025: IFRX, GREE, IPHA, TSLL, SQQQ, NVDA, PFE, BBAI, OSCR, IONQ, HLN, THS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy IFRX?
Source: NASDAQ.COM
NASDAQ 100 Pre-Market Performance: The NASDAQ 100 Pre-Market Indicator is up 380.3 points to 25,440.11, with a total pre-market volume of 219,886,694 shares traded.
Active Stocks Overview: InflaRx N.V. (IFRX) and Greenidge Generation Holdings Inc. (GREE) are among the most active stocks, with IFRX trading at $2.01 and GREE at $2.02, both showing positive movements.
Earnings Reports and Forecasts: IFRX and Innate Pharma S.A. (IPHA) are scheduled to release earnings reports soon, with IPHA showing a significant forecasted increase in earnings per share compared to last year.
Stock Recommendations: Several stocks, including NVIDIA Corporation (NVDA) and IonQ, Inc. (IONQ), are currently in the "buy range" according to Zacks, indicating positive market sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IFRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IFRX
Wall Street analysts forecast IFRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IFRX is 12.67 USD with a low forecast of 6.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.825
Low
6.00
Averages
12.67
High
24.00
Current: 0.825
Low
6.00
Averages
12.67
High
24.00
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
InflaRx to Participate in Investor Conferences
- Investor Conference Schedule: InflaRx will participate in the Guggenheim Securities Biotech Summit on February 11-12, 2026, in New York, conducting one-on-one investor meetings on February 11 to enhance engagement and transparency with investors.
- Virtual Conference Participation: The company will also attend the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with a virtual presentation on February 25, further expanding its investor base.
- Product Development Progress: InflaRx's lead program, izicopan (INF904), an orally administered small molecule inhibitor, has shown promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies, expected to provide treatment options for various inflammatory diseases.
- Innovative Drug Development: The company has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated disease-modifying activity and tolerability in multiple clinical studies, highlighting its innovative potential in anti-inflammatory therapies.
See More
InflaRx Cuts 30% Workforce to Focus on Izicopan Development
- Cost-Cutting Measures: InflaRx announced a 30% workforce reduction and significant cuts to Gohibic-related commercial spending to enhance capital efficiency and support further development of izicopan, expecting a one-time charge of approximately $7 million.
- Cash Flow Outlook: Following the restructuring, InflaRx anticipates its cash runway will extend into mid-2027, and despite reduced spending, it will continue to support the BARDA-sponsored Gohibic clinical trial, ensuring its availability under emergency use authorization in the U.S.
- R&D Priority Shift: The company is prioritizing izicopan, planning to advance its development in hidradenitis suppurativa and other inflammatory and immunology indications, demonstrating a strong commitment to new drug development.
- Market Opportunity Assessment: InflaRx continues to evaluate partnership opportunities for Gohibic in both the U.S. and Europe and plans to engage with the FDA on a potential development path for vilobelimab in pyoderma gangrenosum, showcasing its adaptability in the market.
See More
InflaRx Revives Vilobelimab Development with Positive Phase 3 Data, FDA Talks Ahead
- Clinical Trial Progress: InflaRx's Phase 3 trial for vilobelimab shows a 20.8% improvement in complete target ulcer closure compared to placebo, setting the stage for upcoming FDA discussions despite non-significant results.
- Post-Hoc Analysis Results: Further analyses reveal an average treatment effect of -45.4% in target ulcer volume for vilobelimab, with significant improvements noted by Week 26, indicating potential for sustained treatment benefits.
- Strategic Partnership Plans: InflaRx intends to meet with the FDA to discuss future development pathways for vilobelimab, considering collaboration with partners rather than allocating significant resources independently, highlighting a focus on izicopan (INF904).
- Market Reaction: Following the latest updates, IFRX shares rose by 7.92% to $1.09, reflecting market optimism regarding the company's future prospects.
See More
ARS Pharma's Neffy Approved in China for Allergy Treatment
- Market Breakthrough: ARS Pharma's neffy has received approval from China's NMPA, becoming the first needle-free epinephrine nasal spray for emergency allergy treatment, with commercial availability expected in spring 2026, addressing the growing demand for allergy treatments and further expanding the company's global market presence.
- Market Potential: Neffy generated $31.3 million in U.S. sales in Q3 2025, demonstrating strong market adoption, and the upcoming launch in China is anticipated to significantly boost overall revenue and enhance brand influence.
- Strategic Positioning: This approval marks neffy's successful entry into multiple global markets, including the U.S., U.K., E.U., Japan, and Australia, underscoring the company's leadership in the global allergy treatment sector.
- Future Outlook: With the product's commercialization in China, ARS Pharma plans to strengthen its collaboration with Pediatrix Therapeutics, leveraging its marketing rights in China to drive sales growth and increase market share.
See More
InflaRx Terminates Phase 3 Trial of Vilobelimab, Reveals Potential Efficacy Signals
- Trial Termination: InflaRx terminated its Phase 3 trial of Vilobelimab for pyoderma gangrenosum in May 2025, yet post-hoc analyses revealed that 20.8% of patients achieved complete remission, indicating potential efficacy worth further exploration.
- Positive Patient Response: Among patients receiving Vilobelimab, 36.4% achieved over a 50% reduction in ulcer volume compared to only 16.7% in the placebo group, highlighting the drug's significant potential impact on improving patient quality of life.
- Good Safety Profile: Safety data indicated that adverse events associated with Vilobelimab were mostly mild to moderate, suggesting a favorable tolerance profile that could facilitate its future clinical applications.
- Future Development Plans: InflaRx intends to meet with the FDA to discuss alternative endpoints and is considering pursuing further development in pyoderma gangrenosum in collaboration with a partner, demonstrating the company's ongoing commitment to this therapeutic area.
See More
InflaRx Reports 20.8% Efficacy Improvement for Vilobelimab in Pyoderma Gangrenosum Study
- Study Termination Context: InflaRx N.V. announced the early termination of its Phase 3 study for vilobelimab in pyoderma gangrenosum due to futility, highlighting the challenges and risks associated with clinical trials.
- Efficacy Data Analysis: Recent in-depth data analysis reveals that vilobelimab achieved a 20.8% efficacy in complete target ulcer closure compared to 16.7% for placebo, indicating its potential role in certain neutrophilic skin diseases.
- Key Secondary Endpoint Improvement: Key secondary endpoints showed improvement in favor of vilobelimab over placebo, further supporting its clinical application potential and efficacy.
- FDA Meeting Plans: The company expects to meet with the FDA to discuss a potential path forward for vilobelimab, indicating its strategic focus on future market opportunities and development planning.
See More
InflaRx to Participate in Investor Conferences
- Investor Conference Schedule: InflaRx will participate in the Guggenheim Securities Biotech Summit on February 11-12, 2026, in New York, conducting one-on-one investor meetings on February 11 to enhance engagement and transparency with investors.
- Virtual Conference Participation: The company will also attend the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with a virtual presentation on February 25, further expanding its investor base.
- Product Development Progress: InflaRx's lead program, izicopan (INF904), an orally administered small molecule inhibitor, has shown promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies, expected to provide treatment options for various inflammatory diseases.
- Innovative Drug Development: The company has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated disease-modifying activity and tolerability in multiple clinical studies, highlighting its innovative potential in anti-inflammatory therapies.
See More
InflaRx Cuts 30% Workforce to Focus on Izicopan Development
- Cost-Cutting Measures: InflaRx announced a 30% workforce reduction and significant cuts to Gohibic-related commercial spending to enhance capital efficiency and support further development of izicopan, expecting a one-time charge of approximately $7 million.
- Cash Flow Outlook: Following the restructuring, InflaRx anticipates its cash runway will extend into mid-2027, and despite reduced spending, it will continue to support the BARDA-sponsored Gohibic clinical trial, ensuring its availability under emergency use authorization in the U.S.
- R&D Priority Shift: The company is prioritizing izicopan, planning to advance its development in hidradenitis suppurativa and other inflammatory and immunology indications, demonstrating a strong commitment to new drug development.
- Market Opportunity Assessment: InflaRx continues to evaluate partnership opportunities for Gohibic in both the U.S. and Europe and plans to engage with the FDA on a potential development path for vilobelimab in pyoderma gangrenosum, showcasing its adaptability in the market.
See More
InflaRx Revives Vilobelimab Development with Positive Phase 3 Data, FDA Talks Ahead
- Clinical Trial Progress: InflaRx's Phase 3 trial for vilobelimab shows a 20.8% improvement in complete target ulcer closure compared to placebo, setting the stage for upcoming FDA discussions despite non-significant results.
- Post-Hoc Analysis Results: Further analyses reveal an average treatment effect of -45.4% in target ulcer volume for vilobelimab, with significant improvements noted by Week 26, indicating potential for sustained treatment benefits.
- Strategic Partnership Plans: InflaRx intends to meet with the FDA to discuss future development pathways for vilobelimab, considering collaboration with partners rather than allocating significant resources independently, highlighting a focus on izicopan (INF904).
- Market Reaction: Following the latest updates, IFRX shares rose by 7.92% to $1.09, reflecting market optimism regarding the company's future prospects.
See More
ARS Pharma's Neffy Approved in China for Allergy Treatment
- Market Breakthrough: ARS Pharma's neffy has received approval from China's NMPA, becoming the first needle-free epinephrine nasal spray for emergency allergy treatment, with commercial availability expected in spring 2026, addressing the growing demand for allergy treatments and further expanding the company's global market presence.
- Market Potential: Neffy generated $31.3 million in U.S. sales in Q3 2025, demonstrating strong market adoption, and the upcoming launch in China is anticipated to significantly boost overall revenue and enhance brand influence.
- Strategic Positioning: This approval marks neffy's successful entry into multiple global markets, including the U.S., U.K., E.U., Japan, and Australia, underscoring the company's leadership in the global allergy treatment sector.
- Future Outlook: With the product's commercialization in China, ARS Pharma plans to strengthen its collaboration with Pediatrix Therapeutics, leveraging its marketing rights in China to drive sales growth and increase market share.
See More
InflaRx Terminates Phase 3 Trial of Vilobelimab, Reveals Potential Efficacy Signals
- Trial Termination: InflaRx terminated its Phase 3 trial of Vilobelimab for pyoderma gangrenosum in May 2025, yet post-hoc analyses revealed that 20.8% of patients achieved complete remission, indicating potential efficacy worth further exploration.
- Positive Patient Response: Among patients receiving Vilobelimab, 36.4% achieved over a 50% reduction in ulcer volume compared to only 16.7% in the placebo group, highlighting the drug's significant potential impact on improving patient quality of life.
- Good Safety Profile: Safety data indicated that adverse events associated with Vilobelimab were mostly mild to moderate, suggesting a favorable tolerance profile that could facilitate its future clinical applications.
- Future Development Plans: InflaRx intends to meet with the FDA to discuss alternative endpoints and is considering pursuing further development in pyoderma gangrenosum in collaboration with a partner, demonstrating the company's ongoing commitment to this therapeutic area.
See More
InflaRx Reports 20.8% Efficacy Improvement for Vilobelimab in Pyoderma Gangrenosum Study
- Study Termination Context: InflaRx N.V. announced the early termination of its Phase 3 study for vilobelimab in pyoderma gangrenosum due to futility, highlighting the challenges and risks associated with clinical trials.
- Efficacy Data Analysis: Recent in-depth data analysis reveals that vilobelimab achieved a 20.8% efficacy in complete target ulcer closure compared to 16.7% for placebo, indicating its potential role in certain neutrophilic skin diseases.
- Key Secondary Endpoint Improvement: Key secondary endpoints showed improvement in favor of vilobelimab over placebo, further supporting its clinical application potential and efficacy.
- FDA Meeting Plans: The company expects to meet with the FDA to discuss a potential path forward for vilobelimab, indicating its strategic focus on future market opportunities and development planning.
See More
